Drugs in Dev.
Immunology
Undisclosed
China 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Genakumab
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Genakumab is a Antibody drug candidate, which is currently being evaluated in clinical studies for the treatment of Arthritis, Juvenile.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 29, 2023
Lead Product(s) : Genakumab
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Alvotech
Deal Size : Undisclosed
Deal Type : Partnership
Details : Alvotech and Alvotech & CCHT Biopharmaceutical Co., Ltd will be jointly responsible for the development, registration, and supply of their biosimilars in China, while Yangtze River Pharmaceutical will exclusively commercialize the biosimilar candidates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 24, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Alvotech
Deal Size : Undisclosed
Deal Type : Partnership
